Last reviewed · How we verify

NCT06619340

EXPAREL IPSA Block in Knee Arthroplasty

ENROLLING BY INVITATION Phase 4 Last updated 1 October 2024
What this trial tests

Phase 4 trial testing Exparel in Pain, Postoperative in 10 participants. Enrolling by invitation.

Timeline
20 May 2024
Primary endpoint
20 May 2025
31 December 2025

Quick facts

Lead sponsorCampbell Clinic
PhasePhase 4
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment10
Start date20 May 2024
Primary completion20 May 2025
Estimated completion31 December 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Campbell Clinic

Who can join

18 and older, any sex, with Pain, Postoperative or Osteo Arthritis Knee. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a case series to assess the clinical utility of an Intra-articular Posteromedial Surgeon Administered (IPSA) Block in patients undergoing primary unilateral total knee arthroplasty.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Exparel

Trials testing the same drug.

Other recruiting trials for Pain, Postoperative

Currently open trials in the same condition.

Other Campbell Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06619340.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing